BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23642120)

  • 1. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: a prospective study.
    Sahni RD; Balaji V; Varghese R; John J; Tansarli GS; Falagas ME
    Future Microbiol; 2013 May; 8(5):675-80. PubMed ID: 23642120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.
    Ko KS; Suh JY; Peck KR; Lee MY; Oh WS; Kwon KT; Jung DS; Lee NY; Song JH
    Diagn Microbiol Infect Dis; 2007 May; 58(1):111-5. PubMed ID: 17300900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)].
    Rodríguez-Avial C; Rodríguez-Avial I; Hernández E; Picazo JJ
    Rev Esp Quimioter; 2013 Mar; 26(1):43-6. PubMed ID: 23546462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
    Araj GF; Jaber FA
    J Med Liban; 2012; 60(3):142-7. PubMed ID: 23198454
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Sahu M; Saseedharan S; Bhalekar P
    Indian J Med Microbiol; 2017; 35(3):437-438. PubMed ID: 29063896
    [No Abstract]   [Full Text] [Related]  

  • 7. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
    Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.
    Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J
    J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
    Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.
    Oteo J; Bautista V; Lara N; Cuevas O; Arroyo M; Fernández S; Lázaro E; de Abajo FJ; Campos J;
    J Antimicrob Chemother; 2010 Nov; 65(11):2459-63. PubMed ID: 20851815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3.
    Lee SY; Park YJ; Yu JK; Jung S; Kim Y; Jeong SH; Arakawa Y
    J Antimicrob Chemother; 2012 Dec; 67(12):2843-7. PubMed ID: 22893681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.
    Ellington MJ; Livermore DM; Pitt TL; Hall LM; Woodford N
    J Antimicrob Chemother; 2006 Oct; 58(4):848-52. PubMed ID: 16891630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Kapaskelis A; Samonis G
    Int J Antimicrob Agents; 2010 May; 35(5):497-9. PubMed ID: 20226634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study.
    Rajenderan S; Balaji V; Anandan S; Sahni RD; Tansarli GS; Falagas ME
    PLoS One; 2014; 9(7):e103253. PubMed ID: 25068396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
    Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.